Quarterly report pursuant to Section 13 or 15(d)

Document And Entity Information

v2.4.0.6
Document And Entity Information
9 Months Ended
Sep. 30, 2011
Nov. 04, 2011
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag true  
Amendment Description Ligand Pharmaceuticals Incorporated ("the Company") is filing this Amendment No. 1 ("Amended Form 10-Q") to its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2011, which was originally filed with the Securities and Exchange Commission ("SEC") on November 8, 2011 (the "Original Form 10-Q") to restate the Company's unaudited condensed consolidated financial statements for the three and nine-month period ended September 30, 2011 and amend related disclosures in Management's Discussion and Analysis as well as adding pro forma disclosures related to the acquisition of CyDex Pharmaceuticals, Inc. The Original Form 10-Q included $0.2 million and $0.9 million of general and administrative expenses for the three and nine month periods ended September 30, 2011, respectively, which represented acquisition-related costs that the Company paid on behalf of CyDex Pharmaceuticals, Inc. ("CyDex"). During the Company's 2011 year-end close procedures, the Company determined that these acquisition-related costs should have been recorded as a liability. As a result, the Company is filing this Amended Form 10-Q to amend Part 1. "Financial Statements" and Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations," to reflect the following: • General and administrative expenses for the three-month period ended September 30, 2011 have been reduced by $0.2 million to $4.0 million from $4.1 million and general and administrative expenses for the nine-month period ended September 30, 2011 have been reduced by $0.9 million to $11.3 million from $12.1 million ; • Income tax benefit for the nine-month period ended September 30, 2011 has been reduced $0.2 million to $13.4 million from $13.6 million; • Loss from continuing operations for the three-month period ended September 30, 2011 has been decreased by $0.2 million to $3.8 million, or $0.19 per share, from $3.9 million, or $0.20 per share; and • Goodwill and other identifiable intangible assets at September 30, 2011 have been increased by $0.7 million to $72.9 million from $72.2 million. This Amended Form 10-Q also includes currently-dated certifications from the Company's Chief Executive Officer and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. The Company has not modified or updated disclosures presented in the Original Form 10-Q, except as required to specifically reflect the effects of the restatement in the Amended Form 10-Q. Accordingly, this Amended Form 10-Q does not reflect other events occurring after the Original Form 10-Q, nor does it modify or update those disclosures affected by other subsequent events. Information not affected by the restatement is unchanged and reflects the disclosures made at the time of the Original Form 10-Q.  
Entity Central Index Key 0000886163  
Entity Registrant Name LIGAND PHARMACEUTICALS INC  
Current Fiscal Year End Date --12-31  
Document Period End Date Sep. 30, 2011  
Document Fiscal Year Focus 2011  
Document Fiscal Period Focus Q3  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   19,673,693